Skip to main content

From Psych Congress and Psych Congress Regionals

Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and…
A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster…
Physician assistants (PAs) may offer an effective way to ensure patients have access to quality mental health care despite the projected shortage of psychiatrists in the near future, according to a…
Introducing time-limited adaptive stressors has demonstrated a profound effect on patient well-being, but efforts to sidestep stress often overshadow these approaches in today's society, Psych…
A pharmacogenomic test was associated with improved outcomes in patients with major depressive disorder who failed to improve with previous antidepressant treatment, according to a meta-analysis…
A secondary analysis of a study investigating adjunctive pimavanserin for the treatment of patients with major depressive disorder found that it significantly improved insomnia and sleepiness,…
In managing side effects associated with psychotropic drugs, prescribers need to arm themselves with a menu of strategies and opt first for simpler solutions over adding or switching a medication,…
Patients with major depressive disorder had significantly lower odds of filling a written prescription for a new antidepressant if they were nonwhite and antidepressant-naïve, according to an…
Up to 2 years of treatment with lurasidone improved manic symptoms in children and adolescents with bipolar depression, according to a poster presented at Psych Congress 2020.
Back to Top